News Shortcuts from BMJPG journals

Adalimumab maintains remission in Crohn's disease

BMJ 2007; 335 doi: (Published 16 August 2007) Cite this as: BMJ 2007;335:325

Patients with moderate to severe Crohn's disease who had achieved remission after a four week regimen of the cytokine inhibitor adalimumab (CLASSIC I trial) went on to a placebo controlled trial …

View Full Text

Log in

Log in through your institution


* For online subscription